We showed that the bispecific fusion protein 17V05 effectively inhibited multiple proinflammatory cytokines and chemokines, including IL-6, IL-8, CXCL1, and MCP-1, and thus may be effective in treating immune-induced PDA. The gene discussed is CXCL1; the disease is Patent ductus arteriosus.